Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 210 publications
Assessing trial eligibility and real-world response to vedolizumab and ustekinumab in patients with ulcerative colitis.
Journal: Scandinavian journal of gastroenterology
Published: July 06, 2026
New Diagnostic Criteria for Acute Severe Ulcerative Colitis in the Modern Treatment Era: A Modified Delphi Consensus by REFINED-ASUC.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: May 11, 2026
Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab.
Journal: Inflammatory bowel diseases
Published: April 14, 2026
Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalization.
Journal: Journal of Crohn's & colitis
Published: April 14, 2026
Is It Safe? Long-Term Anti-TNF Therapy - Less to Fear Than We Think.
Journal: Digestive diseases and sciences
Published: April 04, 2026
Therapeutic drug monitoring for de-escalating anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.
Journal: Expert review of clinical pharmacology
Published: February 11, 2026
Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease.
Journal: United European gastroenterology journal
Published: December 30, 2025
Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel Disease.
Journal: Journal of clinical medicine
Published: December 10, 2025
Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitment.
Journal: iGIE : innovation, investigation and insights
Published: December 04, 2025
Treatment optimization of subcutaneous infliximab in patients with inflammatory bowel disease.
Journal: Expert review of gastroenterology & hepatology
Published: November 15, 2025
Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease-Authors' Reply.
Journal: Alimentary pharmacology & therapeutics
Published: November 05, 2025
Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease.
Journal: European journal of gastroenterology & hepatology
Published: November 04, 2025
Last Updated: 09/26/2026